Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
$38.16
+0.8%
$38.78
$26.20
$63.50
$1.68B1.42456,246 shs380,597 shs
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
$63.43
-0.6%
$59.10
$10.14
$69.36
$1.66B1.29432,391 shs194,038 shs
CryoPort, Inc. stock logo
CYRX
CryoPort
$8.50
-3.5%
$7.94
$4.58
$9.48
$443.59M1.621.06 million shs461,681 shs
Mesoblast Limited stock logo
MESO
Mesoblast
$12.88
-1.8%
$13.95
$6.00
$22.00
$1.77B2.26146,473 shs362,661 shs
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
+0.79%+0.98%+2.47%+1.35%-21.16%
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
-0.56%-3.00%+1.55%+163.74%+447.28%
CryoPort, Inc. stock logo
CYRX
CryoPort
-3.52%-3.08%+18.72%+27.63%-1.96%
Mesoblast Limited stock logo
MESO
Mesoblast
-1.83%-20.10%-16.53%+10.94%+85.32%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
3.1921 of 5 stars
4.40.00.00.02.94.20.0
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
3.6091 of 5 stars
2.64.00.04.61.51.70.0
CryoPort, Inc. stock logo
CYRX
CryoPort
4.2162 of 5 stars
4.53.00.00.02.23.31.9
Mesoblast Limited stock logo
MESO
Mesoblast
2.1839 of 5 stars
3.61.00.00.02.90.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
2.88
Moderate Buy$97.29154.94% Upside
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
3.11
Buy$64.141.12% Upside
CryoPort, Inc. stock logo
CYRX
CryoPort
3.00
Buy$12.0041.18% Upside
Mesoblast Limited stock logo
MESO
Mesoblast
3.20
Buy$18.0039.75% Upside

Current Analyst Ratings Breakdown

Latest CYRX, MESO, APGE, and CDTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/28/2025
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
8/28/2025
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$78.00 ➝ $87.00
8/14/2025
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
Zacks Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
8/11/2025
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$90.00
8/8/2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
8/8/2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Outperform ➝ Market Outperform$59.00 ➝ $66.00
8/8/2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$53.00 ➝ $74.00
8/8/2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$54.00 ➝ $74.00
8/6/2025
CryoPort, Inc. stock logo
CYRX
CryoPort
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
8/6/2025
CryoPort, Inc. stock logo
CYRX
CryoPort
KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeSector Weight ➝ Overweight$15.00
8/6/2025
CryoPort, Inc. stock logo
CYRX
CryoPort
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform$16.00
(Data available from 9/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
N/AN/AN/AN/A$13.43 per shareN/A
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
$1.27M1,266.60N/AN/A$19.76 per share3.21
CryoPort, Inc. stock logo
CYRX
CryoPort
$228.38M1.86N/AN/A$9.53 per share0.89
Mesoblast Limited stock logo
MESO
Mesoblast
$5.90M279.43N/AN/A$4.21 per share3.06
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
-$182.15M-$4.13N/AN/AN/AN/A-34.65%-32.76%11/11/2025 (Estimated)
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
-$169.83M-$11.13N/AN/AN/AN/A-50.81%-42.46%11/6/2025 (Estimated)
CryoPort, Inc. stock logo
CYRX
CryoPort
-$114.76M$1.336.39N/AN/A37.21%-9.79%-5.42%11/6/2025 (Estimated)
Mesoblast Limited stock logo
MESO
Mesoblast
-$87.96MN/A0.00N/AN/AN/AN/AN/AN/A

Latest CYRX, MESO, APGE, and CDTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2025Q2 2025
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
-$1.03-$1.13-$0.10-$1.13N/AN/A
8/7/2025Q2 2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
-$1.87-$1.65+$0.22-$1.65N/AN/A
8/5/2025Q2 2025
CryoPort, Inc. stock logo
CYRX
CryoPort
-$0.20-$0.29-$0.09$2.05$41.74 million$45.45 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
N/AN/AN/AN/AN/A
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
N/AN/AN/AN/AN/A
CryoPort, Inc. stock logo
CYRX
CryoPort
N/AN/AN/AN/AN/A
Mesoblast Limited stock logo
MESO
Mesoblast
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
N/A
16.36
16.36
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
N/A
16.45
16.45
CryoPort, Inc. stock logo
CYRX
CryoPort
0.39
16.24
15.47
Mesoblast Limited stock logo
MESO
Mesoblast
0.22
0.96
0.63

Institutional Ownership

CompanyInstitutional Ownership
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
79.04%
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
35.82%
CryoPort, Inc. stock logo
CYRX
CryoPort
92.90%
Mesoblast Limited stock logo
MESO
Mesoblast
1.43%

Insider Ownership

CompanyInsider Ownership
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
42.77%
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
7.64%
CryoPort, Inc. stock logo
CYRX
CryoPort
10.10%
Mesoblast Limited stock logo
MESO
Mesoblast
18.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
9146.11 million26.39 millionOptionable
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
9025.36 million23.42 millionNo Data
CryoPort, Inc. stock logo
CYRX
CryoPort
1,18650.07 million45.01 millionOptionable
Mesoblast Limited stock logo
MESO
Mesoblast
80128.00 million103.93 millionOptionable

Recent News About These Companies

Mesoblast Limited (NASDAQ:MESO) Q4 2025 Earnings Call Transcript
Mesoblast (NASDAQ:MESO) Shares Gap Down - What's Next?
Mesoblast Full Year 2025 Earnings: Misses Expectations
Examining the Future: Mesoblast's Earnings Outlook
Examining the Future: Mesoblast's Earnings Outlook
Mesoblast (NASDAQ:MESO) Shares Gap Up - Time to Buy?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Apogee Therapeutics stock logo

Apogee Therapeutics NASDAQ:APGE

$38.16 +0.30 (+0.79%)
Closing price 09/3/2025 04:00 PM Eastern
Extended Trading
$37.69 -0.47 (-1.24%)
As of 09/3/2025 06:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

Cidara Therapeutics stock logo

Cidara Therapeutics NASDAQ:CDTX

$63.43 -0.36 (-0.56%)
Closing price 09/3/2025 04:00 PM Eastern
Extended Trading
$63.44 +0.01 (+0.02%)
As of 09/3/2025 05:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.

CryoPort stock logo

CryoPort NASDAQ:CYRX

$8.50 -0.31 (-3.52%)
Closing price 09/3/2025 04:00 PM Eastern
Extended Trading
$8.52 +0.02 (+0.24%)
As of 09/3/2025 05:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.

Mesoblast stock logo

Mesoblast NASDAQ:MESO

$12.88 -0.24 (-1.83%)
Closing price 09/3/2025 04:00 PM Eastern
Extended Trading
$12.54 -0.34 (-2.64%)
As of 09/3/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.